b'<?xml version="1.0" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">\n<PubmedArticleSet>\n<PubmedArticle>\n    <MedlineCitation Status="In-Data-Review" Owner="NLM">\n        <PMID Version="1">32056262</PMID>\n        <DateRevised>\n            <Year>2020</Year>\n            <Month>08</Month>\n            <Day>04</Day>\n        </DateRevised>\n        <Article PubModel="Print-Electronic">\n            <Journal>\n                <ISSN IssnType="Electronic">1938-3673</ISSN>\n                <JournalIssue CitedMedium="Internet">\n                    <Volume>108</Volume>\n                    <Issue>2</Issue>\n                    <PubDate>\n                        <Year>2020</Year>\n                        <Month>Aug</Month>\n                    </PubDate>\n                </JournalIssue>\n                <Title>Journal of leukocyte biology</Title>\n                <ISOAbbreviation>J. Leukoc. Biol.</ISOAbbreviation>\n            </Journal>\n            <ArticleTitle>Erdheim-Chester disease: An in vivo human model of M\xcf\x95 activation at the crossroad between chronic inflammation and cancer.</ArticleTitle>\n            <Pagination>\n                <MedlinePgn>591-599</MedlinePgn>\n            </Pagination>\n            <ELocationID EIdType="doi" ValidYN="Y">10.1002/JLB.3MR0120-203RR</ELocationID>\n            <Abstract>\n                <AbstractText>Erdheim-Chester disease (ECD) is a rare histiocytosis characterized by infiltration of multiple tissues by CD68<sup>+</sup> foamy M\xcf\x95s (or \'histiocytes\'). Clinical manifestations arise from mass-forming lesions or from tissue and systemic inflammation. ECD histiocytes harbor oncogenic mutations along the MAPK-kinase signaling pathway (BRAF<sup>V600E</sup> in more than half of the patients), and secrete abundant pro-inflammatory cytokines and chemokines. Based on these features, ECD is considered an inflammatory myeloid neoplasm, and is accordingly managed with targeted kinase inhibitors or immunosuppressive and cytokine-blocking agents. Evidence is emerging that maladaptive metabolic changes, particularly up-regulated glycolysis, represent an additional, mutation-driven feature of ECD histiocytes, which sustains deregulated and protracted pro-inflammatory activation and cytokine production. Besides translational relevance to the management of ECD patients and to the development of new therapeutic approaches, recognition of ECD as a natural human model of chronic, maladaptive M\xcf\x95 activation instructs the understanding of M\xcf\x95 dysfunction in other chronic inflammatory conditions.</AbstractText>\n                <CopyrightInformation>\xc2\xa92020 Society for Leukocyte Biology.</CopyrightInformation>\n            </Abstract>\n            <AuthorList CompleteYN="Y">\n                <Author ValidYN="Y">\n                    <LastName>Cavalli</LastName>\n                    <ForeName>Giulio</ForeName>\n                    <Initials>G</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Vita-Salute San Raffaele University, Milan, Italy.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), San Raffaele Scientific Institute, Milan, Italy.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Dagna</LastName>\n                    <ForeName>Lorenzo</ForeName>\n                    <Initials>L</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Vita-Salute San Raffaele University, Milan, Italy.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), San Raffaele Scientific Institute, Milan, Italy.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Biavasco</LastName>\n                    <ForeName>Riccardo</ForeName>\n                    <Initials>R</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Vita-Salute San Raffaele University, Milan, Italy.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>San Raffaele Telethon Institute for Gene Therapy (SR-Tiget), San Raffaele Scientific Institute, Milan, Italy.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Villa</LastName>\n                    <ForeName>Antonello</ForeName>\n                    <Initials>A</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Consorzio MIA, University of Milano-Bicocca, Milan, Italy.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Doglioni</LastName>\n                    <ForeName>Claudio</ForeName>\n                    <Initials>C</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Vita-Salute San Raffaele University, Milan, Italy.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>Pathology Unit, San Raffaele Scientific Institute, Milan, Italy.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Ferrero</LastName>\n                    <ForeName>Elisabetta</ForeName>\n                    <Initials>E</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Division of Experimental Oncology, San Raffaele Scientific Institute, Milan, Italy.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Ferrarini</LastName>\n                    <ForeName>Marina</ForeName>\n                    <Initials>M</Initials>\n                    <Identifier Source="ORCID">https://orcid.org/0000-0003-1015-9632</Identifier>\n                    <AffiliationInfo>\n                        <Affiliation>Division of Experimental Oncology, San Raffaele Scientific Institute, Milan, Italy.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n            </AuthorList>\n            <Language>eng</Language>\n            <GrantList CompleteYN="Y">\n                <Grant>\n                    <Agency>ECD Global Alliance</Agency>\n                    <Country/>\n                </Grant>\n                <Grant>\n                    <GrantID>MFAG 2018 - ID. 22136</GrantID>\n                    <Agency>AIRC</Agency>\n                    <Country/>\n                </Grant>\n            </GrantList>\n            <PublicationTypeList>\n                <PublicationType UI="D016428">Journal Article</PublicationType>\n                <PublicationType UI="D016454">Review</PublicationType>\n            </PublicationTypeList>\n            <ArticleDate DateType="Electronic">\n                <Year>2020</Year>\n                <Month>02</Month>\n                <Day>14</Day>\n            </ArticleDate>\n        </Article>\n        <MedlineJournalInfo>\n            <Country>United States</Country>\n            <MedlineTA>J Leukoc Biol</MedlineTA>\n            <NlmUniqueID>8405628</NlmUniqueID>\n            <ISSNLinking>0741-5400</ISSNLinking>\n        </MedlineJournalInfo>\n        <CitationSubset>IM</CitationSubset>\n        <KeywordList Owner="NOTNLM">\n            <Keyword MajorTopicYN="N">3D culture</Keyword>\n            <Keyword MajorTopicYN="N">BRAF mutation</Keyword>\n            <Keyword MajorTopicYN="N">cell metabolism</Keyword>\n            <Keyword MajorTopicYN="N">cytokines</Keyword>\n            <Keyword MajorTopicYN="N">histiocytosis</Keyword>\n        </KeywordList>\n    </MedlineCitation>\n    <PubmedData>\n        <History>\n            <PubMedPubDate PubStatus="received">\n                <Year>2019</Year>\n                <Month>08</Month>\n                <Day>29</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="revised">\n                <Year>2020</Year>\n                <Month>01</Month>\n                <Day>16</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="accepted">\n                <Year>2020</Year>\n                <Month>01</Month>\n                <Day>20</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="pubmed">\n                <Year>2020</Year>\n                <Month>2</Month>\n                <Day>15</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="medline">\n                <Year>2020</Year>\n                <Month>2</Month>\n                <Day>15</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="entrez">\n                <Year>2020</Year>\n                <Month>2</Month>\n                <Day>15</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n        </History>\n        <PublicationStatus>ppublish</PublicationStatus>\n        <ArticleIdList>\n            <ArticleId IdType="pubmed">32056262</ArticleId>\n            <ArticleId IdType="doi">10.1002/JLB.3MR0120-203RR</ArticleId>\n        </ArticleIdList>\n        <ReferenceList>\n            <Title>REFERENCES</Title>\n            <Reference>\n                <Citation>Emile JF, Abla O, Fraitag S, Histiocyte Society, et\xc2\xa0al. Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood. 2016;127:2672-2681.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Lichtenstein L. Histiocytosis X; integration of eosinophilic granuloma of bone, Letterer-Siwe disease, and Sch\xc3\xbcller-Christian disease as related manifestations of a single nosologic entity. AMA Arch Pathol. 1953;56:84-102.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Berres ML, Merad M, Allen CE. Progress in understanding the pathogenesis of Langerhans cell histiocytosis: back to Histiocytosis X. Br J Haematol. 2015;169:3-13.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Swerdlow SH, Campo E, Harris NL, et\xc2\xa0al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Geneva, Switzerland: WHO Press; 2008.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Haroche J, Cohen-Aubart F, Charlotte F, et\xc2\xa0al. The histiocytosis Erdheim-Chester disease is an inflammatory myeloid neoplasm. Expert Rev Clin Immunol. 2015;11:1033-1042.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Haroche J, Cohen-Aubart F, Rollins BJ, et\xc2\xa0al. Histiocytoses: emerging neoplasia behind inflammation. Lancet Oncol. 2017;18:e113-e125.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Chester W. Uber lipoidgranulomatose. Virchows Arch A Pathol Anat Histol. 1930;279:561-602.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Diamond EL, Dagna L, Hyman DM, et\xc2\xa0al. Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease. Blood. 2014;124:483-492.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Cavalli G, Guglielmi B, Berti A, Campochiaro C, Sabbadini MG, Dagna L. The multifaceted clinical presentations and manifestations of Erdheim-Chester disease: comprehensive review of the literature and of 10 new cases. Ann Rheum Dis. 2013;72:1691-1695.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Campochiaro C, Tomelleri A, Cavalli G, Berti A, Dagna L. Erdheim-Chester disease. Eur J Intern Med. 2015;26:223-229.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Diamond EL, Hatzoglou V, Patel S, et\xc2\xa0al. Diffuse reduction of cerebral grey matter volumes in Erdheim-Chester disease. Orphanet J Rare Dis. 2016;11:109.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Chiapparini L, Cavalli G, Langella T, et\xc2\xa0al. Adult leukoencephalopathies with prominent infratentorial involvement can be caused by Erdheim-Chester disease. J Neurol. 2018;265:273-284.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Cavalli G, Berti A, Campochiaro C, Dagna L. Diagnosing Erdheim-Chester disease. Ann Rheum Dis. 2013;72:e19.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Vaglio A, Salvarani C, Buzio C. Retroperitoneal fibrosis. Lancet. 2006;367:241-251.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Kamisawa T, Zen Y, Pillai S, Stone JH. IgG4-related disease. Lancet. 2015;385:1460-1471.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Braiteh F, Boxrud C, Esmaeli B, Kurzrock R. Successful treatment of Erdheim-Chester disease, a non-Langerhans-cell histiocytosis, with interferon-alpha. Blood. 2005;106:2992-2994.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Arnaud L, Hervier B, N\xc3\xa9el A, et\xc2\xa0al. CNS involvement and treatment with interferon-\xce\xb1 are independent prognostic factors in Erdheim-Chester disease: a multicenter survival analysis of 53 patients. Blood. 2011;117:2778-2782.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Hervier B, Arnaud L, Charlotte F, et\xc2\xa0al. Treatment of Erdheim-Chester disease with long-term high-dose interferon-\xce\xb1. Semin Arthritis Rheum. 2012;41:907-913.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Nakhleh A, Slobodin G, Elias N, Bejar J, Odeh M. Rapid progression to cardiac tamponade in Erdheim-Chester disease despite treatment with interferon alpha. Mod Rheumatol. 2016;26:621-624.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Estrada-Veras JI, O\'Brien KJ, Boyd LC, et\xc2\xa0al. The clinical spectrum of Erdheim-Chester disease: an observational cohort study. Blood Adv. 2017;1:357-366.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Cavalli G, Dinarello CA. Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies. Rheumatology. 2015;54:2134-2144.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Colafrancesco S, Priori R, Valesini G, et\xc2\xa0al. Response to interleukin-1 inhibitors in 140 Italian patients with adult-onset still\'s disease: a multicentre retrospective observational study. Front Pharmacol. 2017;8:369.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Cavalli G, Dinarello CA. Anakinra therapy for non-cancer inflammatory diseases. Front Pharmacol. 2018;9:1157.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Cavalli G, Tomelleri A, De Luca G, et\xc2\xa0al. Efficacy of canakinumab as first-line biologic agent in adult-onset Still\'s disease. Arthritis Res Ther. 2019;21:54.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Aouba A, Georgin-Lavialle S, Pagnoux C, et\xc2\xa0al. Rationale and efficacy of interleukin-1 targeting in Erdheim-Chester disease. Blood. 2010;116:4070-4076.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Courcoul A, Vignot E, Chapurlat R. Successful treatment of Erdheim-Chester disease by interleukin-1 receptor antagonist protein. Joint Bone Spine. 2014;81:175-177.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Diamond EL, Abdel-Wahab O, Durham BH, et\xc2\xa0al. Anakinra as efficacious therapy for 2 cases of intracranial Erdheim-Chester disease. Blood. 2016;128:1896-1898.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Cohen-Aubart F, Maksud P, Saadoun D, et\xc2\xa0al. Variability in the efficacy of the IL1 receptor antagonist anakinra for treating Erdheim-Chester disease. Blood. 2016;127:1509-1512.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Tomelleri A, Cavalli G, De Luca G, et\xc2\xa0al. Treating heart inflammation with interleukin-1 blockade in a case of Erdheim-Chester disease. Front Immunol. 2018;9:1233.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Tran TA, Pariente D, Guitton C, Delwail A, Barat-Houari M, Meinzer U. Treatment of Erdheim-Chester disease with canakinumab. Rheumatology. 2014;53:2312-2314.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Dagna L, Corti A, Langheim S, et\xc2\xa0al. Tumor necrosis factor \xce\xb1 as a master regulator of inflammation in Erdheim-Chester disease: rationale for the treatment of patients with infliximab. J Clin Oncol. 2012;30:e286-290.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Cohen-Aubart F, Maksud P, Emile JF, et\xc2\xa0al. Efficacy of infliximab in the treatment of Erdheim-Chester disease. Ann Rheum Dis. 2018;77:1387-1390.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Berti A, Cavalli G, Guglielmi B, et\xc2\xa0al. Tocilizumab in patients with multisystem Erdheim-Chester disease. Oncoimmunology. 2017;6:e1318237.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Haroche J, Cohen-Aubart F, Emile JF, et\xc2\xa0al. Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation. Blood. 2013;121:1495-1500.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Haroche J, Cohen-Aubart F, Emile JF, et\xc2\xa0al. Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAF(V600E)-mutated Erdheim-Chester disease. J Clin Oncol. 2015;33:411-418.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Hyman DM, Puzanov I, Subbiah V, et\xc2\xa0al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med. 2015;373:726-736.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Diamond EL, Subbiah V, Lockhart AC, et\xc2\xa0al. Vemurafenib for BRAF V600-mutant Erdheim-Chester disease and langerhans cell histiocytosis: analysis of data from the histology-independent, phase 2, open-label VE-BASKET study. JAMA Oncol. 2018;4:384-388.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>The Lancet Haematology. 2017. Orphan drug approval for Erdheim-Chester disease. Lancet Haematol. 4:e562.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Cohen Aubart F, Emile JF, Carrat F, et\xc2\xa0al. Targeted therapies in 54 patients with Erdheim-Chester disease, including follow-up after interruption (the LOVE study). Blood. 2017;130:1377-1380.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Diamond EL, Durham BH, Ulaner GA, et\xc2\xa0al. Efficacy of MEK inhibition in patients with histiocytic neoplasms. Nature. 2019;567:521-524.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Stoppacciaro A, Ferrarini M, Salmaggi C, et\xc2\xa0al. Immunohistochemical evidence of a cytokine and chemokine network in three patients with Erdheim-Chester disease: implications for pathogenesis. Arthritis Rheum. 2006;54:4018-4022.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Laman JD, Leenen PJ, Annels NE, Hogendoorn PC, Egeler RM. Langerhans-cell histiocytosis \xe2\x80\x98insight into DC biology\xe2\x80\x99. Trends Immunol. 2003;24:190-196.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Dagna L, Girlanda S, Langheim S, et\xc2\xa0al. Erdheim-Chester disease: report on a case and new insights on its immunopathogenesis. Rheumatology. 2010;49:1203-1206.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Sica A, Mantovani A. Macrophage plasticity and polarization: in vivo veritas. J Clin Invest. 2012;122:787-795.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Arnaud L, Gorochov G, Charlotte F, et\xc2\xa0al. Systemic perturbation of cytokine and chemokine networks in Erdheim-Chester disease: a single-center series of 37 patients. Blood. 2011;117:2783-2790.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Ferrero E, Belloni D, Corti A, Doglioni C, Dagna L, Ferrarini M. TNF-\xce\xb1 in Erdheim-Chester disease pericardial effusion promotes endothelial leakage in vitro and is neutralized by infliximab. Rheumatology. 2014;53:198-200.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Gatalica Z, Bilalovic N, Palazzo JP, et\xc2\xa0al. Disseminated histiocytoses biomarkers beyond BRAFV600E: frequent expression of PD-L1. Oncotarget. 2015;6:19819-19825.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Keir ME, Francisco LM, Sharpe AH. PD-1 and its ligands in T-cell immunity. Curr Opin Immunol. 2007;19:309-314.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Wherry EJ, Kurachi M. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol. 2015;15:486-499.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252-264.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Wei SC, Duffy CR, Allison JP. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 2018;8:1069-1086.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Jones DH, Kong YY, Penninger JM. Role of RANKL and RANK in bone loss and arthritis. Ann Rheum Dis. 2002;61(Suppl 2):ii32-9.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Eming SA, Wynn TA, Martin P. Inflammation and metabolism in tissue repair and regeneration. Science. 2017;356:1026-1030.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Schutyser E, Richmond A, Van Damme J. Involvement of CC chemokine ligand 18 (CCL18) in normal and pathological processes. J Leukoc Biol. 2005;78:14-26.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Derynck R, Akhurst RJ. Differentiation plasticity regulated by TGF-beta family proteins in development and disease. Nat Cell Biol. 2007;9:1000-1004.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Pacini G, Cavalli G, Tomelleri A, et\xc2\xa0al. The fibrogenic chemokine CCL18 is associated with disease severity in Erdheim-Chester disease. Oncoimmunology. 2018;7:e1440929.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Badalian-Very G, Vergilio JA, Degar BA, et\xc2\xa0al. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood. 2010;116:1919-1923.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Sahm F, Capper D, Preusser M, et\xc2\xa0al. BRAFV600E mutant protein is expressed in cells of variable maturation in Langerhans cell histiocytosis. Blood. 2012;120:e28-34.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Haroche J, Charlotte F, Arnaud L, et\xc2\xa0al. High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. Blood. 2012;120:2700-2703.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Blombery P, Wong SQ, Lade S, Prince HM. Erdheim-Chester disease harboring the BRAF V600E mutation. J Clin Oncol. 2012;30:e331-2.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Cangi MG, Biavasco R, Cavalli G, et\xc2\xa0al. BRAFV600E-mutation is invariably present and associated to oncogene-induced senescence in Erdheim-Chester disease. Ann Rheum Dis. 2015;74:1596-1602.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Davies H, Bignell GR, Cox C, et\xc2\xa0al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949-954.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Emile JF, Diamond EL, H\xc3\xa9lias-Rodzewicz Z, et\xc2\xa0al. Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease. Blood. 2014;124:3016-3019.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Diamond EL, Durham BH, Haroche J, et\xc2\xa0al. Diverse and targetable kinase alterations drive histiocytic neoplasms. Cancer Discov. 2016;6:154-165.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Durham BH. Molecular characterization of the histiocytoses: neoplasia of dendritic cells and macrophages. Semin Cell Dev Biol. 2019;86:62-76.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Papo M, Cohen-Aubart F, Trefond L, et\xc2\xa0al. Systemic histiocytosis (Langerhans cell histiocytosis, Erdheim-Chester disease, Destombes-Rosai-Dorfman disease): from oncogenic mutations to inflammatory disorders. Curr Oncol Rep. 2019;21:62.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Gomez Perdiguero E, Klapproth K, Schulz C, et\xc2\xa0al. Tissue-resident macrophages originate from yolk-sac-derived erythro-myeloid progenitors. Nature. 2015;518:547-551.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Guilliams M, Mildner A, Yona S. Developmental and functional heterogeneity of monocytes. Immunity. 2018;49:595-613.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Milne P, Bigley V, Bacon CM, et\xc2\xa0al. Hematopoietic origin of Langerhans cell histiocytosis and Erdheim-Chester disease in adults. Blood. 2017;130:167-175.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Durham BH, Roos-Weil D, Baillou C, et\xc2\xa0al. Functional evidence for derivation of systemic histiocytic neoplasms from hematopoietic stem/progenitor cells. Blood. 2017;130:176-180.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Hervier B, Haroche J, Arnaud L, French Histiocytoses Study Group, et\xc2\xa0al. Association of both Langerhans cell histiocytosis and Erdheim-Chester disease linked to the BRAFV600E mutation. Blood. 2014;124:1119-1126.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Berres ML, Lim KP, Peters T, et\xc2\xa0al. BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups. J Exp Med. 2014;211:669-683.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Papo M, Diamond EL, Cohen-Aubart F, et\xc2\xa0al. High prevalence of myeloid neoplasms in adults with non-Langerhans cell histiocytosis. Blood. 2017;130:1007-1013.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Bonnet P, Chasset F, Moguelet P, EMSED and MINHEMON, et\xc2\xa0al. Erdheim-Chester disease associated with chronic myelomonocytic leukemia harboring the same clonal mutation. Haematologica. 2019;104:e530-e533.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Johnson WT, Patel P, Hernandez A, et\xc2\xa0al. Langerhans cell histiocytosis and Erdheim-Chester disease, both with cutaneous presentations, and papillary thyroid carcinoma all harboring the BRAF(V600E) mutation. J Cutan Pathol. 2016;43:270-275.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Cavalli G, Biavasco R, Borgiani B, Dagna L. Oncogene-induced senescence as a new mechanism of disease: the paradigm of Erdheim-Chester disease. Front Immunol. 2014;5:281.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Mooi WJ, Peeper DS. Oncogene-induced cell senescence - halting on the road to cancer. N Engl J Med. 2006;355:1037-1046.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Pampaloni F, Reynaud EG, Stelzer EH. The third dimension bridges the gap between cell culture and live tissue. Nat Rev Mol Cell Biol. 2007;8:839-845.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Becker JL, Souza GR. Using space-based investigations to inform cancer research on Earth. Nat Rev Cancer. 2013;13:315-327.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Ferrarini M, Steimberg N, Ponzoni M, et\xc2\xa0al. Ex-vivo dynamic 3-D culture of human tissues in the RCCS\xe2\x84\xa2 bioreactor allows the study of multiple myeloma biology and response to therapy. PLoS One. 2013;8:e71613.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Ferrarini M, Steimberg N, Boniotti J, et\xc2\xa0al. 3D-dynamic culture models of multiple myeloma. Methods Mol Biol. 2017;1612:177-190.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Villa A, Belloni D, Vergani B, et\xc2\xa0al. 3D culture of Erdheim-Chester disease tissues unveils histiocyte metabolism as a new therapeutic target. Ann Rheum Dis. 2019;78(6):862-864.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Ward PS, Thompson CB. Metabolic reprogramming: a cancer hallmark even Warburg did not anticipate. Cancer Cell. 2012;21:297-308.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Hay N. Reprogramming glucose metabolism in cancer: can it be exploited for cancer therapy. Nat Rev Cancer. 2016;16:635-649.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Mu\xc3\xb1oz-Pinedo C, El Mjiyad N, Ricci JE. Cancer metabolism: current perspectives and future directions. Cell Death Dis. 2012;3:e248.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Kawada K, Toda K, Sakai Y. Targeting metabolic reprogramming in KRAS-driven cancers. Int J Clin Oncol. 2017;22:651-659.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Artyomov MN, Sergushichev A, Schilling JD. Integrating immunometabolism and macrophage diversity. Semin Immunol. 2016;28:417-424.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Russell DG, Huang L, VanderVen BC. Immunometabolism at the interface between macrophages and pathogens. Nat Rev Immunol. 2019;19:291-304.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Childs BG, Baker DJ, Wijshake T, Conover CA, Campisi J, van Deursen JM. Senescent intimal foam cells are deleterious at all stages of atherosclerosis. Science. 2016;354:472-477.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Cohen-Aubart F, Guerin M, Poupel L, et\xc2\xa0al. Hypoalphalipoproteinemia and BRAFV600E mutation are major predictors of aortic infiltration in the Erdheim-Chester disease. Arterioscler Thromb Vasc Biol. 2018;388:1913-1925.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Locati M, Curtale G, Mantovani A. Diversity, mechanisms, and significance of macrophage plasticity. Annu Rev Pathol. 2019;15:123-147.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Murray PJ, Allen JE, Biswas SK, et\xc2\xa0al. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity. 2014;41:14-20.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Biswas SK, Allavena P, Mantovani A. Tumor-associated macrophages: functional diversity, clinical significance, and open questions. Semin Immunopathol. 2013;35:585-600.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Mantovani A, Marchesi F, Malesci A, Laghi L, Allavena P. Tumour-associated macrophages as treatment targets in oncology. Nat Rev Clin Oncol. 2017;14:399-416.</Citation>\n            </Reference>\n            <Reference>\n                <Citation>Chinetti-Gbaguidi G, Colin S, Staels B. Macrophage subsets in atherosclerosis. Nat Rev Cardiol. 2015;12:10-17.</Citation>\n            </Reference>\n        </ReferenceList>\n    </PubmedData>\n</PubmedArticle>\n\n</PubmedArticleSet>'